Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.
Journal: Future oncology (London, England)
Published: July 14, 2026
Fludarabine and Total Body Irradiation 800 cGy or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil (OmitMMF trial).
Journal: Transplantation and cellular therapy
Published: June 04, 2026
Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation.
Journal: Transplantation proceedings
Published: October 20, 2025
Irradiated Bone Marrow Volume is Associated With Hematologic Toxicity in Patients With Multiple Myeloma.
Journal: International journal of radiation oncology, biology, physics
Published: May 29, 2024
Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.
Journal: BMJ case reports
Published: June 22, 2022
Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Journal: Hematological oncology
Published: August 13, 2019
Showing 1-6 of 6
Last Updated: 09/26/2026